Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Resverlogix Corp (RVX.TO)

Resverlogix Corp (RVX.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Resverlogix Announces Change to Its Board of Directors

Calgary, Alberta--(Newsfile Corp. - February 21, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") today announced that Shawn Lu has stepped down from the Board of Directors, effective...

RVXCF : 0.0416 (+9.47%)
RVX.TO : 0.0600 (+9.09%)
Resverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic Benefits

Calgary, Alberta--(Newsfile Corp. - January 11, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", "the Company") today announced publication of an article, entitled, "The BET inhibitor apabetalone decreases...

RVXCF : 0.0416 (+9.47%)
RVX.TO : 0.0600 (+9.09%)
Stocks in play: Resverlogix Corp.

Today announced the publication of a peer-reviewed article, entitled "Apabetalone, a Clinical-stage, ...

RVX.TO : 0.0600 (+9.09%)
Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy

Calgary, Alberta--(Newsfile Corp. - October 4, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix") today announced the publication of a peer-reviewed article, entitled "Apabetalone, a Clinical-stage,...

RVXCF : 0.0416 (+9.47%)
RVX.TO : 0.0600 (+9.09%)
Resverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 Diabetes

Amsterdam, Netherlands and Calgary, Alberta--(Newsfile Corp. - August 29, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix") (TSX:RVX) today announced that new guidelines published by the European Society...

RVXCF : 0.0416 (+9.47%)
RVX.TO : 0.0600 (+9.09%)
Resverlogix Announces Warrant Repricing and One-Year Extension

Calgary, Alberta--(Newsfile Corp. - June 29, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announces that certain of its 27,461,157 common share purchase warrants (the "Warrants")...

RVX.TO : 0.0600 (+9.09%)
RVXCF : 0.0416 (+9.47%)
Resverlogix Announces Voting Results from the 2023 Meeting of Shareholders

Calgary, Alberta--(Newsfile Corp. - June 20, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", or the "Corporation") today held its Annual Meeting of Shareholders (the "Meeting") in Calgary, Alberta.During...

RVX.TO : 0.0600 (+9.09%)
RVXCF : 0.0416 (+9.47%)
Resverlogix Announces New Insights into the Mechanism of Apabetalone's Cardioprotective Benefit in Chronic Kidney Disease Patients

Calgary, Alberta--(Newsfile Corp. - June 12, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix") today announced a peer-reviewed article, entitled, "Apabetalone Downregulates Fibrotic, Inflammatory and...

RVX.TO : 0.0600 (+9.09%)
RVXCF : 0.0416 (+9.47%)
Resverlogix Announces One-Year Extension of Debenture

Calgary, Alberta--(Newsfile Corp. - March 20, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today that it has closed a one-year extension of Company's US$6.0 million secured...

RVX.TO : 0.0600 (+9.09%)
RVXCF : 0.0416 (+9.47%)
Resverlogix Announces New Research Highlighting Apabetalone's Potential Benefits in Cardiovascular Disease, Heart Failure, and COVID-19

Calgary, Alberta--(Newsfile Corp. - March 2, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix") today announced the publication of two articles in peer-reviewed scientific journals. The first, entitled...

RVX.TO : 0.0600 (+9.09%)
RVXCF : 0.0416 (+9.47%)

Barchart Exclusives

Can This 'Magnificent 7' Underperformer Climb As High As It Did Last Year?
Following the company's disastrous first quarter results, investing in Tesla now carries significant risk. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar